| Size | Price | Stock | Qty |
|---|---|---|---|
| 100mg |
|
||
| 250mg |
|
||
| 500mg | |||
| Other Sizes |
| Targets |
L-Hydroorotic acid serves as a substrate for dihydroorotate dehydrogenase (DHODH), an enzyme in the de novo synthesis of pyrimidines. By being a substrate for DHODH, it plays a role in the pyrimidine biosynthesis pathway. It is not a drug target itself but a metabolic intermediate.
|
|---|---|
| ln Vitro |
In vitro, L-Hydroorotic acid is a substrate for dihydroorotase and dihydroorotate dehydrogenase (DHODH). Its conversion to L-ureidosuccinic acid by dihydroorotase and to orotic acid by DHODH can be measured in enzyme assays. It is a standard compound used in enzymology studies.
|
| ln Vivo |
In vivo, L-Hydroorotic acid is a naturally occurring metabolite in the pyrimidine biosynthesis pathway. It is found in various organisms, including Saccharomyces cerevisiae, humans, Escherichia coli, and mice. Its levels can be used as a biomarker for certain metabolic conditions.
|
| Enzyme Assay |
The in vitro enzyme assay for L-Hydroorotic acid typically measures its conversion by dihydroorotase or dihydroorotate dehydrogenase (DHODH). These assays use the purified enzyme and the compound as a substrate, and the production of the product (L-ureidosuccinic acid or orotic acid) is measured. These assays are used to study enzyme kinetics and to screen for inhibitors of these enzymes.
|
| Cell Assay |
In vitro cellular assays for L-Hydroorotic acid are not commonly performed, as it is a metabolic intermediate. However, its effects on pyrimidine synthesis can be studied in cell culture by measuring the incorporation of labeled precursors into pyrimidines or by measuring the levels of pyrimidine nucleotides.
|
| Animal Protocol |
L-Hydroorotic acid is a naturally occurring compound that is produced and metabolized in the body as part of the pyrimidine biosynthesis pathway. It is an intermediate that is rapidly converted to other metabolites. Its pharmacokinetic properties are those of an endogenous metabolite, not a drug.
|
| ADME/Pharmacokinetics |
L-Hydroorotic acid is a naturally occurring compound and is generally considered safe. It is not a drug and is not intended for therapeutic use. Its toxicity would be related to its role in metabolism, but specific toxicity data are not applicable as it is not administered as a pharmaceutical agent.
|
| Toxicity/Toxicokinetics |
L-Hydroorotic acid (L-Dihydroorotic acid) is a naturally occurring intermediate in the pyrimidine biosynthesis pathway. It is a substrate for dihydroorotate dehydrogenase (DHODH). It is used as a research tool in enzymology and metabolic studies. It is not a drug and is not approved for therapeutic use.
|
| References | |
| Additional Infomation |
(S)-Dihydroorotic acid is the (S)-enantiomer of dihydroorotic acid and an intermediate in pyridine metabolism. It is found in Saccharomyces cerevisiae, humans, Escherichia coli, and mice. It is the conjugate acid of (S)-dihydroorotic acid and also the enantiomer of (R)-dihydroorotic acid. L-Dihydroorotic acid has been reported in Arabidopsis thaliana, humans, and other organisms with relevant data. L-Dihydroorotic acid is a metabolite found or produced in Saccharomyces cerevisiae.
|
| Molecular Formula |
C5H6N2O4
|
|---|---|
| Molecular Weight |
158.1121
|
| Exact Mass |
158.032
|
| CAS # |
5988-19-2
|
| PubChem CID |
439216
|
| Appearance |
White to off-white solid powder
|
| Density |
1.9±0.1 g/cm3
|
| Boiling Point |
524.0±60.0 °C at 760 mmHg
|
| Melting Point |
254-255 °C (dec.)(lit.)
|
| Flash Point |
270.7±32.9 °C
|
| Vapour Pressure |
0.0±3.1 mmHg at 25°C
|
| Index of Refraction |
1.714
|
| LogP |
-2.29
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
1
|
| Heavy Atom Count |
11
|
| Complexity |
225
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
C1[C@H](NC(=O)NC1=O)C(=O)O
|
| InChi Key |
UFIVEPVSAGBUSI-REOHCLBHSA-N
|
| InChi Code |
InChI=1S/C5H6N2O4/c8-3-1-2(4(9)10)6-5(11)7-3/h2H,1H2,(H,9,10)(H2,6,7,8,11)/t2-/m0/s1
|
| Chemical Name |
(4S)-2,6-dioxo-1,3-diazinane-4-carboxylic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMF : 33.33 mg/mL (~210.80 mM)
DMSO : ~25 mg/mL (~158.12 mM) H2O : ~5 mg/mL (~31.62 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (15.81 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (15.81 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (15.81 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. Solubility in Formulation 4: ≥ 2.5 mg/mL (15.81 mM) (saturation unknown) in 10% DMF 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 5: ≥ 2.5 mg/mL (15.81 mM) (saturation unknown) in 10% DMF 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 6: 7.69 mg/mL (48.64 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with ultrasonication (<60°C). |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 6.3247 mL | 31.6236 mL | 63.2471 mL | |
| 5 mM | 1.2649 mL | 6.3247 mL | 12.6494 mL | |
| 10 mM | 0.6325 mL | 3.1624 mL | 6.3247 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
